An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C

Trial Profile

An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 07 Jul 2016

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms TRICO
  • Sponsors Roche
  • Most Recent Events

    • 26 Aug 2014 The actual patient number is 165 as per ClinicalTrials.gov record but EudraCT gives the number as 150. I have retained NCT info as it is recently updated.
    • 07 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top